Structural Heart

This structural heart channel includes news, videos, podcasts and other content related to diagnosis and treatment of structural heart disease. Topics covered include heart valve repair and replacement, transcatheter aortic valve replacement (TAVR), transcatheter mitral valve replacement (TMVR), transcatheter tricuspid valve replacement (TTVR), left atrial appendage (LAA) occlusion, heart failure interventional device therapies, and closing holes in the heart using, including occlusion of atrial septal defects (ASDs), ventricular septal defects (VSDs) and patent foramen ovales (PFOs).

Former National Football League (NFL) player Ed White (left) needed a new aortic heart valve but decided to wait several months for the FDA to approve TACR for low-risk patients so he would not have to undergo open heart surgery. Democratic presidential candidate Sen. Bernie Sanders received two stents after he was hospitalized with chest pain was hospitalized with chest pain on Oct. 1 in Las Vegas. The event brought PCI to the forefront of national news in October.

Former National Football League (NFL) player Ed White (left) needed a new aortic heart valve, but decided to wait several months for the FDA to approve TAVR for low-risk patients so he would not have to undergo open heart surgery. Democratic presidential candidate Sen. Bernie Sanders received two stents after he was hospitalized with chest pain was hospitalized with chest pain on Oct. 1 in Las Vegas. The event brought PCI to the forefront of national news in October. 

Feature | November 01, 2019 | Dave Fornell, Editor
November 1, 2019 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
 Retired National Football League (NFL) star Ed White, the former Chargers guard and four-time Pro Bowler, waited until the FDA approved TAVR for low-risk patients like himself to avoid open-heart surgery.

Retired National Football League (NFL) star Ed White, the former Chargers guard and four-time Pro Bowler, waited until the FDA approved TAVR for low-risk patients like himself to avoid open-heart surgery.

Feature | Heart Valve Technology | October 29, 2019
October 29, 2019 — When Scripps cardiologists discovered early in 2019 that retired National Football League (NFL)...
The Gore Cardioform ASD Occluder received European CE mark clearance in early October. The device offers a percutaneous, transcatheter closure option for the ostium secundum atrial septal defects (ASDs).
News | October 28, 2019
October 28, 2019 — The Gore Cardioform ASD Occluder received European CE mark clearance in early October. The device...
Videos | Vascular Closure Devices | October 17, 2019
Ashish Pershad, M.D., chief of interventional cardiology, Banner University Medical Center, Phoenix, explains the trend...
Videos | Structural Heart | October 16, 2019
Vivian Ng, M.D., assistant professor of medicine and an interventional cardiologist at the NewYork-Presbyterian/...
TCT 2019 Late-breaking Presentations in the main arena. The top interventional cardiology studies of 2019. #TCT #TCT19 #TCT2019
Feature | TCT | October 11, 2019
October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-breaking...
Videos | Heart Valve Technology | October 09, 2019
Torsten Vahl, M.D., director of experimental and translational research, Structural Heart and Valve Center and at the...
Videos | TCT | October 04, 2019
Chandan Devireddy, M.D., offers insights about what he saw as the top take aways from the 2019 Transcatheter...
A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography. Study Finds Sustained Benefit for TAVR vs. SAVR at One Year. #TCT2019 #TCT19

A Sapien 3 TAVR valve in position as seen under GE Assist guidance on angiography.

News | Heart Valve Technology | October 04, 2019
October 4, 2019 – A new analysis of the PARTNER 3 Trial data found a modest, but significant, improvement in one-year...
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve...
Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and intermediate surgical risk who underwent Sapien 3 transcatheter aortic valve replacement (TAVR) had similar rates of death and disabling stroke compared to those who had surgical aortic valve replacement (SAVR). However, TAVR using a transthoracic approach had poorer outcomes compared to SAVR. #TCT2019
News | Heart Valve Technology | October 03, 2019
October 3, 2019 – Five-year results from the PARTNER 2A Trial found patients with severe aortic stenosis (AS) and...
COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the COAPT Trial demonstrated that reducing severe secondary mitral...
Videos | University of Colorado Hospital | October 02, 2019
Interview with John Carroll, M.D., director of interventional cardiology, Robert Quaife, M.D., director of advanced...
The Boston Scientiofic Acurate Neo TAVR valve did not meet non-inferiority to the Sapien 3 valve in patients with severe aortic stenosis. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019
October 2, 2019 – The first randomized trial to compare the safety and efficacy of the new Boston Scientific Acurate...
The Portico FDA investigational device exemption (IDE) study found that 30-day safety and one-year effectiveness outcomes of a novel self-expanding transcatheter aortic valve replacement (TAVR) system for patients with severe aortic stenosis (AS) at high or extreme-risk for surgery was noninferior to contemporary FDA-approved TAVR systems. #TAVR #TCT2019
News | Heart Valve Technology | October 02, 2019
October 2, 2019 – The Abbott Portico FDA investigational device exemption (IDE) study found that 30-day safety and one-...